Impact of Preoperative α-Fetoprotein Level on Disease-Free Survival After Liver Transplantation for Hepatocellular Carcinoma
Corresponding Author
Fabrice Muscari
Department of Digestive Surgery and Liver Transplantation, CHU Rangueil, 1 Avenue Jean Poulhès, 31059 Toulouse Cedex, France
Department of Epidemiology and Inserm U1027, Toulouse, France
[email protected]Search for more papers by this authorJean-Pascal Guinard
Department of Digestive Surgery and Liver Transplantation, CHU Rangueil, 1 Avenue Jean Poulhès, 31059 Toulouse Cedex, France
Search for more papers by this authorNassim Kamar
Department of Organ Transplantation and Nephrology, CHU Rangueil, Toulouse, France
Search for more papers by this authorJean-Marie Peron
Department of Hepatology, CHU Purpan, Toulouse, France
Search for more papers by this authorPhilippe Otal
Department of Radiology, CHU Rangueil, Toulouse, France
Search for more papers by this authorBertrand Suc
Department of Digestive Surgery and Liver Transplantation, CHU Rangueil, 1 Avenue Jean Poulhès, 31059 Toulouse Cedex, France
Search for more papers by this authorCorresponding Author
Fabrice Muscari
Department of Digestive Surgery and Liver Transplantation, CHU Rangueil, 1 Avenue Jean Poulhès, 31059 Toulouse Cedex, France
Department of Epidemiology and Inserm U1027, Toulouse, France
[email protected]Search for more papers by this authorJean-Pascal Guinard
Department of Digestive Surgery and Liver Transplantation, CHU Rangueil, 1 Avenue Jean Poulhès, 31059 Toulouse Cedex, France
Search for more papers by this authorNassim Kamar
Department of Organ Transplantation and Nephrology, CHU Rangueil, Toulouse, France
Search for more papers by this authorJean-Marie Peron
Department of Hepatology, CHU Purpan, Toulouse, France
Search for more papers by this authorPhilippe Otal
Department of Radiology, CHU Rangueil, Toulouse, France
Search for more papers by this authorBertrand Suc
Department of Digestive Surgery and Liver Transplantation, CHU Rangueil, 1 Avenue Jean Poulhès, 31059 Toulouse Cedex, France
Search for more papers by this authorAbstract
Background
Preoperative α-fetoprotein (AFP) levels may have an influence on disease-free survival (DFS) of patients after liver transplantation for hepatocellular carcinoma (HCC) located on a cirrhotic liver.
Methods
Between 2000 and 2009, two groups were distinguished according to preoperative AFP level: normal-level group (<10 ng/ml) and increased-level group (>10 ng/ml). The increased-level group was further divided into three levels of preoperative AFP: 10–150, 150–500, and ≥500 ng/ml. DFS and recurrence rates were compared. All patients underwent transplantation using the preoperative 5/5 criteria.
Results
Of the 122 patients in this study, 63 had normal and 59 had increased preoperative AFP. There were no differences between the two groups concerning perioperative or pathologic data. Those with an increased preoperative AFP level had a significantly shorter 5-year DFS, and their recurrence rate was higher than that of the normal AFP group. The 5-year DFS and recurrence rates were 71 and 4 %, respectively, for those with normal AFP; 57 and 10 %, respectively, for those with AFP 10–150 ng/ml; 46 and 24 %, respectively, for those with AFP 150–500 ng/ml; and 28 and 62 %, respectively, for those with AFP ≥500 ng/ml.
Conclusions
This study shows the prognostic value of preoperative AFP levels on DFS after a liver transplant for HCC in a population of patients undergoing transplantation with the same preoperative criteria.
Conflict of interest
None.
References
- 1YooHY, PattCH, GeschwindJF et al. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J Clin Oncol (2003) 21: 4329–43351458144610.1200/JCO.2003.11.137
- 2HemmingAW, CattralMS, ReedAI et al. Liver transplantation for hepatocellular carcinoma. Ann Surg (2001) 5: 652–65910.1097/00000658-200105000-00009
- 3MazzaferroV, RegaliaE, DociR et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 334: 693–699859442810.1056/NEJM199603143341104
- 4JonasS, BechsteinWO, SteinmuellerT et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology (2001) 33: 1080–10861134323510.1053/jhep.2001.23561
- 5FiguerasJ, JaurrietaE, VallsC et al. Survival after liver transplantation in cirrhotic patients with and without hepatocellular carcinoma: a comparative study. Hepatology (1997) 25: 1485–1489918577210.1002/hep.510250629
- 6LlovetJM, BruixJ, FusterJ et al. Liver transplantation for small hepatocellular carcinoma: the tumour-node-metastasis classification does not have prognostic power. Hepatology (1998) 27: 1572–1577962032910.1002/hep.510270616
- 7HerreroJI, SangroB, QuirogaJ et al. Influence of tumour characteristic on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl (2001) 7: 631–6361146023110.1053/jlts.2001.25458
- 8DuffyJP, VardanianA, BenjaminE et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg (2007) 246: 502–5111771745410.1097/SLA.0b013e318148c704
- 9LlovetJM, BurroughsA, BruixJ Hepatocellular carcinoma. Lancet (2003) 362: 1907–19171466775010.1016/S0140-6736(03)14964-1
- 10El-SeragHB, MasonAL Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med (1999) 340: 745–7501007240810.1056/NEJM199903113401001
- 11YaoFY, FerrellL, BassNM et al. Liver transplantation for hepatocellular carcinoma: an expansion of the tumour size limits does not adversely impact survival. Hepatology (2001) 33: 1394–14031139152810.1053/jhep.2001.24563
- 12SueC, KrisV Expansion of criteria for liver transplantation in HCC: a slippery slope?. Gastroenterology (2002) 122: 579–58210.1016/S0016-5085(02)80327-4
- 13RoayaieS, FrischerJS, EmreSH et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 cm. Ann Surg (2002) 235: 533–5391192361010.1097/00000658-200204000-00012
- 14OnacaN, DavisGL, GoldsteinRM et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma: a report from the International Registry of Hepatic Tumor in Liver Transplantation. Liver Transpl (2007) 13: 391–3991731886510.1002/lt.21095
- 15MuscariF, FoppaB, KamarN et al. Liberal selection criteria for liver transplantation for hepatocellular carcinoma. Br J Surg (2009) 96: 785–7911952662110.1002/bjs.6619
- 16SugawaraY, TamuraS, MakuuchiM Living donor liver transplantation for hepatocellular: Tokyo University series. Dig Dis (2007) 25: 310–3121796006510.1159/000106910
- 17TosoC, KnetemanNM, ShapiroAMJ et al. The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria. Transpl Int (2009) 22: 869–8751938607510.1111/j.1432-2277.2009.00882.x
- 18ChaC, FongY, JarnaginWR et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg (2003) 197: 753–7581458540910.1016/j.jamcollsurg.2003.07.003
- 19ScattonO, ZalinskiS, TerrisB et al. Hepatocellular carcinoma developed on compensated cirrhosis: resection as a selection tool for liver transplantation. Liver Transpl (2008) 14: 779–7881850837010.1002/lt.21431
- 20RegimbeauJM, AbdallaEK, VautheyJN et al. Risk factors for early death due to recurrence after liver resection for hepatocellular carcinoma: results of a multicenter study. J Surg Oncol (2004) 85: 36–411469608510.1002/jso.10284
- 21WangCC, IyerSI, LowJK et al. Perioperative factors affecting long term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol (2009) 16: 1832–18421936562510.1245/s10434-009-0448-y
- 22NgKK, LoCM, LiuCL et al. Survival analysis of patients with transplantable recurrent hepatocellular carcinoma. Arch Surg (2008) 143: 68–741820915510.1001/archsurg.2007.15
- 23PawlikTM, GleisnerAL, AndersRA et al. Preoperative assessment of hepatocellular carcinoma tumor grade using needle biopsy: implications for transplant eligibility. Ann Surg (2007) 245: 435–4421743555110.1097/01.sla.0000250420.73854.ad
- 24ShermanM The resurrection of alphafetoprotein. J Hepatol (2010) 52: 939–9402039500710.1016/j.jhep.2010.02.006
- 25FujiokaM, NakashimaY, NakashimaO et al. Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma (abstract). Hepatology (2001) 34: 1128–11341173200210.1053/jhep.2001.29202
- 26FarinatiF, MarinoD, De GiorgoM et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol (2006) 101: 524–5321654228910.1111/j.1572-0241.2006.00443.x
- 27VibertE, AzoulayD, HotiE et al. Progression of alpha-fetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transpl (2010) 10: 129–13710.1111/j.1600-6143.2009.02750.x
- 28TosoC, AsthanaS, BigamDL et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology (2009) 49: 832–8381915242610.1002/hep.22693
- 29WangZX, SongSH, TengF et al. A single-center retrospective analysis of liver transplantation on 225 patients with hepatocellular carcinoma. Clin Transpl (2010) 24: 752–75710.1111/j.1399-0012.2009.01172.x
- 30OnacaN, DavisGL, JenningsLW et al. Improved results of transplantation for hepatocellular carcinoma: a report from the International Registry of Hepatic Tumors in liver transplantation. Liver Transpl (2009) 15: 574–5801947980010.1002/lt.21738
- 31HanK, TzimasGN, BarkunJS et al. Preoperative alpha-fetoprotein slope is predictive of hepatocellular carcinoma recurrence after liver transplantation. Can J Gastroenterol (2007) 21: 39–4517225881
- 32ChenCL, ConcejeroAM Liver transplantation for hepatocellular carcinoma in the world: the Taiwan experience. J Hepatobiliary Pancreat Sci (2010) 17: 555–5581976036010.1007/s00534-009-0166-7
- 33BruixJ, ShermanM, LlovetJM et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona–2000 EASL ConferenceߝEuropean Association for the Study of Liver. J Hepatol (2001) 35: 421–4301159260710.1016/S0168-8278(01)00130-1
- 34MuscariF, SucB, AguirreJ et al. Orthotopic liver transplantation with vena cava preservation in cirrhotic patients: is systematic temporary portocaval anastomosis a justified procedure?. Transpl Proc (2005) 37: 2159–216210.1016/j.transproceed.2005.03.005
- 35MuscariF, SucB, VigourouxD et al. Blood salvage autotransfusion during transplantation for hepatocarcinoma: does it increase the risk of neoplastic recurrence?. Transpl Int (2005) 18: 1236–12391622115310.1111/j.1432-2277.2005.00207.x
- 36DecaensT, Roudot-ThorovalF, Hadni-BressonS et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl (2006) 12: 1769–179110.1002/lt.20884
- 37SotiropoulosGC, MalagoM, MolmentiEP et al. Liver transplantation for hepatocellular carcinoma in cirrosis: is clinical tumor classification before transplantation realistic?. Transplantation (2005) 79: 483–4871572917610.1097/01.TP.0000152801.82734.74
- 38FiguerasJ, IbanezL, RamosE et al. Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transpl (2001) 7: 877–8831167998610.1053/jlts.2001.27856
- 39ShettyK, TimminsK, BrensingerC et al. Liver transplantation for hepatocellular carcinoma: validation of present selection criteria in predicting outcome. Liver Transpl (2004) 10: 911–9181523737710.1002/lt.20140
- 40De CarlisL, GiacomoniA, PirottaV et al. Surgical treatment of hepatocellular cancer in the era of hepatic transplantation. J Am Coll Surg (2003) 196: 887–8971278842510.1016/S1072-7515(03)00140-6
- 41StuartKE, AnandAJ, JenkinsRL Hepatocellular carcinoma in the United States: prognostic features, treatment, outcome and survival. Cancer (1996) 77: 2217–2222863508710.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M
10.1002/(SICI)1097-0142(19960601)77:11<2217::AID-CNCR6>3.0.CO;2-M CAS PubMed Web of Science® Google Scholar
- 42LlovetJM, FusterJ, BruixJ Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology (1999) 30: 1434–14401057352210.1002/hep.510300629
- 43YamashikiN, GaynorJJ, KatoT et al. Competing risks analysis of predictors of delisting owing to tumor progression in liver transplantation candidates with hepatocellular carcinoma. Am J Transpl (2004) 4: 774–78110.1111/j.1600-6143.2004.00412.x
- 44ShanSL, MoFK, JohnsonPJ et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol (2009) 27: 446–452
- 45RiazA, RyuRK, KulikLM et al. Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol (2009) 27: 5734–57421980567110.1200/JCO.2009.23.1282
- 46ChenLT, ShiahHS, ChaoY et al. Alpha-fetoprotein response in advanced hepatocellular carcinoma receiving cytostatic agent. J Clin Oncol (2009) 27: e2711991786610.1200/JCO.2009.23.8311
- 47Sandhu L, Sandroussi C, Guba M, et al (2011) Live donor versus decreased donor liver transplantation for hepatocellular carcinoma: comparative survival and recurrence. Liver Transpl Dec 5
